A phase ii trial of short course fludarabine, mitoxantrone, rituximab followed by 90y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma

导出原文传递

翻译打印收藏纠错

作者： Zinzani,P.L. ^[1] ; Tani,M. ^[2] ; Pulsoni,A. ^[3] ; DeRenzo,A. ^[4] ; Stefoni,V. ^[5] ; Broccoli,A. ; Montini,G.C. ; Fina,M. ; Pellegrini,C. ; Gandolfi,L. ; Cavalieri,E. ; Torelli,F. ; Scopinaro,F. ; Argnani,L. ; Quirini,F. ; Derenzini,E. ; Rossi,M. ; Pileri,S. ; Fanti,S. ; Baccarani,M.

作者单位： Department of Nuclear Medicine, Policlinico Sant'Orsola-Malpighi, University of Bologna, Bologna ^[1] Department of Radiological Sciences, La Sapienza University, Rome, Italy ^[2] Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant'Orsola-Malpighi ^[3] Department of Cellular Biotechnology and Hematology, La Sapienza University, Rome, Italy ^[4] Division of Hematology, Federico II University, Naples, Italy ^[5]

关键词 90Y-ibritumomab tiuxetan Fludarabine Follicular lymphoma Mitoxantrone Radioimmunotherapy Rituximab

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交